Join us for one of three live webinars and hear Canadian experts discuss whether Colchicine is the third pillar of secondary prevention of ASVCD. Register today and join us live on the date of your choice to ask your questions directly to the experts.

Faculty

  • Shaun Goodman, MD, MSc, FRCPC, FACC, FAHA, FESC, FCCS
  • Ruth McPherson, MD, PhD, FRCPC, FRCS
  • Jean-Claude Tardif, CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS
  • Robert Welsh, MD, FRCPC, FESC, FACC, FAHA

Learning Objectives:

  • Recognize residual cardiovascular risk for patients with ASCVD despite the use of standard therapy
  • Assess the role of inflammation in ASCVD and the evidence for colchicine in patients with ASCVD and ACS
  • Evaluate the practical application of colchicine in the management of ASCVD through a case-based scenario